glp1InjectableNot FDA-approvedResearch chemicalInvestigational — not approved by any regulatorPhase 3 trials ongoing
RetatrutideBenefits, Dosage & Interactions
Retatrutide is an investigational drug that acts as a triple-receptor agonist, targeting receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Research on Retatrutide focuses on weight loss, blood sugar control, and heart and circulatory health. Retatrutide is administered by injection rather than orally.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
~6 days
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- 1 mg, 4 mg, 8 mg and 12 mg once weekly were the phase 2 maintenance amounts[1]
- Route studied
- Subcutaneous injection[1]
- Frequency
- Once weekly with stepwise escalation[1]
- Cycle length
- 48 weeks in the phase 2 trial[1]
- Half-life
- Approximately 6 days, supporting weekly dosing[1]
- Storage
- No approved consumer product exists, so no label storage instructions are published[1]
Reported for Retatrutide in the cited sources. Published ranges are not dosing advice.
Retatrutide compared with similar compounds
| Attribute | Semaglutide | Tirzepatide | Retatrutide | Liraglutide |
|---|---|---|---|---|
| Class | GLP-1 receptor agonist | GIP/GLP-1 dual receptor agonist | GIP/GLP-1/glucagon triple agonist | GLP-1 receptor agonist |
| Route | Subcutaneous once weekly | Subcutaneous once weekly | Subcutaneous once weekly | Subcutaneous once daily |
| Half-life | ~7 days | ~5 days | ~6 days | ~13 hours |
| Evidence grade | Strong | Strong | Moderate | Strong |
| Oral stability | Oral tablet form exists (with SNAC absorption enhancer) | Not orally available | Not orally available | Not orally available |
| Typical published cycle | Ongoing while prescribed | Ongoing while prescribed | Investigational — phase 3 ongoing | Ongoing while prescribed |
| Main studied use | Type 2 diabetes and weight management | Type 2 diabetes and obesity | Obesity (investigational) | Type 2 diabetes and weight management |
References & evidence
Documents the Retatrutide entry is written from. Each number matches an inline marker above.
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialJastreboff AM, Kaplan LM, Frías JP, et al. · New England Journal of Medicine · 2023 · Peer-reviewed · PMID 37366315
How to track Retatrutide doses
Retatrutide is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Retatrutide is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Retatrutide comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 144 h, effects and timing shifts show up over days rather than instantly. Review Retatrutide alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Retatrutide dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Retatrutide studied for?
What is Retatrutide?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Retatrutide is an investigational drug that acts as a triple-receptor agonist, targeting receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This multi-pronged approach distinguishes it from earlier generation medications that often target only one or two of these pathways. It is being developed primarily for the treatment of obesity and related metabolic conditions.
The GIP, GLP-1, and glucagon receptors are integral to metabolic regulation. GIP and GLP-1 are incretin hormones that, among other effects, stimulate insulin secretion in a glucose-dependent manner, suppress glucagon secretion, slow gastric emptying, and promote satiety. Glucagon, broadly known for its role in increasing blood glucose, also has complex metabolic effects that, when modulated by agonists like retatrutide, may contribute to energy expenditure and fat utilization. By activating all three receptors, retatrutide aims to leverage these synergistic effects to achieve significant improvements in weight management and glycemic control, as described in early clinical trials (Eli Lilly and Company announcements, clinical trial registries). As an injectable compound, its dose is user-directed and must be set by a licensed clinician.
What does the research say about Retatrutide?
Tap a section to expand.
Retatrutide functions as a triple-receptor agonist, simultaneously binding to and activating the GIP, GLP-1, and glucagon receptors. Each of these receptors plays a distinct yet interconnected role in metabolic homeostasis:
* **GIP Receptor (Glucose-dependent insulinotropic polypeptide):** Activation of the GIP receptor contributes to enhanced insulin secretion from pancreatic beta cells, particularly in the presence of elevated glucose levels. It also has effects on fat metabolism and energy storage.
* **GLP-1 Receptor (Glucagon-like peptide-1):** Activation of the GLP-1 receptor leads to increased glucose-dependent insulin secretion, suppression of glucagon release from the pancreas, delayed gastric emptying, and a reduction in appetite through central nervous system pathways. These actions collectively contribute to improved glycemic control and reduced food intake.
* **Glucagon Receptor:** While glucagon is typically associated with raising blood glucose, agonism of the glucagon receptor by retatrutide in conjunction with GIP and GLP-1 agonism is hypothesized to enhance energy expenditure and directly promote lipolysis (fat breakdown), contributing to greater weight loss. This unique combination of actions, confirmed by preclinical and early clinical data (e.g., studies referenced by Eli Lilly and Company), is designed to exert a comprehensive influence on glucose metabolism, energy balance, and body weight.
Source for this section: Sources for How does Retatrutide work?: Jumps to this entry in the sources and references list at the end of the page.
Clinical studies of retatrutide have primarily investigated its potential benefits in the context of weight management and improvements in metabolic parameters, particularly in individuals with obesity.
* **Significant Weight Loss:** The most prominent benefit observed in phase 2 clinical trials has been substantial body weight reduction. Initial findings suggest that retatrutide may induce a greater percentage of weight loss compared to existing single or dual incretin agonists (Clinical trial results reported by Eli Lilly and Company, scientific presentations). This effect is attributed to its multifaceted action on GIP, GLP-1, and glucagon receptors, influencing appetite, satiety, and energy expenditure.
* **Improved Glycemic Control:** While primarily studied for weight loss, retatrutide's GIP and GLP-1 agonism also contributes to better blood glucose regulation. This includes enhancements in fasting glucose levels and measures of long-term glycemic control, such as HbA1c, in individuals with or without type 2 diabetes (Data from clinical trials, e.g., as reported in *The New England Journal of Medicine* for similar compounds).
* **Reduction in Cardiovascular Risk Factors:** Beyond weight and glucose, preliminary data indicates potential improvements in other cardiometabolic risk factors, such as blood pressure and lipid profiles, which often accompany significant weight loss (Observations from phase 2 studies, consistent with effects of other incretin-based therapies as noted by Mayo Clinic). Further research is ongoing to fully characterize these effects.
These benefits are under continued investigation in larger-scale clinical trials.
The evidence supporting retatrutide's effects primarily stems from preclinical studies and early-phase clinical trials, particularly phase 2 studies focused on dose-response and efficacy in humans.
A significant phase 2 clinical trial, details of which have been reported by the manufacturer and presented at scientific meetings (e.g., American Diabetes Association Scientific Sessions), demonstrated dose-dependent reductions in body weight. For instance, participants receiving higher doses of retatrutide achieved substantial percentage body weight loss over several months, with some cohorts demonstrating reductions beyond what has been observed with other agents in similar trial settings. These findings have been published in peer-reviewed medical journals, such as *The New England Journal of Medicine*, for comparable incretin-based therapies, illustrating the mechanism's potential.
These studies have also shown improvements in various cardiometabolic parameters, including changes in lipid levels, blood pressure, and markers of glycemic control (e.g., HbA1c, fasting glucose), which are consistent with the known effects of GIP, GLP-1, and glucagon receptor agonism. While these early results are promising, larger phase 3 trials are necessary to confirm long-term efficacy, safety, and comparative effectiveness against established treatments. The data remains under active investigation by organizations such as Eli Lilly and Company.
Like other compounds targeting incretin pathways, retatrutide can be associated with certain side effects, predominantly gastrointestinal in nature.
Commonly reported side effects from clinical trials include (Eli Lilly and Company clinical trial reports, similar to effects noted in FDA labels for related drugs):
* Nausea
* Vomiting
* Diarrhea
* Constipation
* Abdominal pain
These gastrointestinal effects are often dose-dependent and tend to be more pronounced during the initial phase of treatment or with dose escalation. They may decrease over time as the body adjusts to the medication.
Less common, but potentially more serious side effects, observed with similar compounds and theoretically possible with retatrutide, include:
* **Pancreatitis:** Inflammation of the pancreas. Patients should be monitored for symptoms such as severe, persistent abdominal pain.
* **Gallbladder problems:** Including cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder).
* **Hypoglycemia (low blood sugar):** Particularly when used in combination with other glucose-lowering medications like sulfonylureas or insulin. Monotherapy typically presents a lower risk.
* **Renal impairment:** Worsening of kidney function, especially in patients with pre-existing kidney conditions or those experiencing severe gastrointestinal side effects leading to dehydration.
* **Allergic reactions:** Such as rash, itching, swelling, or difficulty breathing, though considered rare.
Patients experiencing any severe or persistent side effects should seek medical attention. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Several important warnings and precautions are associated with the use of retatrutide, derived from its pharmacology and observations in clinical trials, as well as from experience with analogous compounds (e.g., information from DrugBank, FDA-approved drug labels for GLP-1 agonists).
* **Pancreatitis Risk:** Patients should be informed about the characteristic symptoms of acute pancreatitis (severe, persistent abdominal pain, sometimes radiating to the back, with or without vomiting). If pancreatitis is suspected, retatrutide should be discontinued, and appropriate medical management initiated. A history of pancreatitis may be a risk factor.
* **Gallbladder Disease:** Rapid weight loss associated with drugs like retatrutide can increase the risk of cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder). Patients should be monitored for symptoms.
* **Hypoglycemia Risk:** The risk of hypoglycemia is increased when retatrutide is co-administered with other glucose-lowering therapies, particularly insulin or sulfonylureas. Dosage adjustments of these concomitant medications may be necessary.
* **Acute Kidney Injury:** There have been post-marketing reports of acute kidney injury and worsening of chronic renal failure with GLP-1 receptor agonists, sometimes requiring hemodialysis. Some of these events occurred in patients without known underlying renal disease who experienced nausea, vomiting, or diarrhea leading to dehydration. Caution should be exercised in patients with renal impairment.
* **Thyroid C-cell Tumors:** In rodent studies, GLP-1 receptor agonists (a class retatrutide belongs to) caused thyroid C-cell tumors (adenomas and carcinomas). It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Retatrutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Adequate counseling and monitoring should be undertaken.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Retatrutide is contraindicated in specific patient populations due to potential risks, based on its mechanism of action and preclinical/clinical data, similar to other incretin-based therapies (e.g., as outlined in FDA-approved drug labels).
* **Personal or Family History of Medullary Thyroid Carcinoma (MTC):** Retatrutide is contraindicated in patients with a personal or family history of MTC. As a GLP-1 receptor agonist, it has demonstrated an association with thyroid C-cell tumors in rodent studies, though the relevance to humans is not yet definitively established.
* **Multiple Endocrine Neoplasia syndrome type 2 (MEN 2):** Patients with MEN 2 are also contraindicated, given the increased risk of MTC in this syndrome.
* **Prior Severe Hypersensitivity Reaction to Retatrutide:** Individuals who have experienced a severe allergic or hypersensitivity reaction (e.g., anaphylaxis, angioedema) to retatrutide or any component of its formulation should not use it.
* **Pregnancy and Breastfeeding:** Currently, there is insufficient data on human pregnancy and lactation to establish safety. Therefore, use in pregnant or breastfeeding individuals is generally not recommended, and a careful risk-benefit assessment by a clinician is required. Women of childbearing potential should discuss effective contraception with their healthcare provider during treatment.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
While specific drug-drug interaction studies for retatrutide are ongoing, based on its multi-receptor agonism and known effects of similar compounds, certain combinations warrant caution or contraindication (information derived from FDA labels for related GLP-1 receptor agonists and general pharmacological principles).
* **Other GLP-1 Receptor Agonists or DPP-4 Inhibitors:** Concurrent use with other GLP-1 receptor agonists (e.g., semaglutide, liraglutide) or dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin, saxagliptin) is generally not recommended. This is due to the potential for additive pharmacological effects, an increased risk of side effects (particularly gastrointestinal), and a lack of additional clinical benefit from overlapping mechanisms.
* **Insulin and Insulin Secretagogues (e.g., Sulfonylureas):** When initiating retatrutide therapy in patients already on insulin or sulfonylureas, a reduction in the dose of these concomitant medications may be necessary to minimize the risk of hypoglycemia. Close glucose monitoring is essential.
* **Oral Medications with a Narrow Therapeutic Index:** Due to retatrutide's potential to delay gastric emptying, it may affect the absorption of concomitantly administered oral medications. Particular caution is advised for drugs that require rapid gastrointestinal absorption or those with a narrow therapeutic index. Patients should be monitored for altered effects of such medications. For instance, an oral contraceptive's efficacy might be reduced if its absorption is significantly delayed.
* **Alcohol:** While not a strict contraindication, alcohol consumption can increase the risk of hypoglycemia and exacerbate gastrointestinal side effects. It is generally advisable to moderate alcohol intake.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Retatrutide is an injectable compound intended for once-weekly administration (Eli Lilly and Company reports from clinical trials). The specific timing within the day (e.g., morning or evening) typically does not significantly affect its efficacy, and administration with or without food is generally acceptable. Consistent weekly administration on the same day is important to maintain stable drug levels. If a dose is missed, patients should follow specific instructions provided by their healthcare professional regarding when to administer the missed dose and when to resume the regular schedule. Adherence to a consistent schedule helps maximize therapeutic benefits and minimize fluctuations that could lead to side effects. The dose is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Retatrutide?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Retatrutide?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Insulin (Rapid) | Caution | Compound pairConfidence: theoretical | Combining a GLP-1 with rapid insulin increases hypoglycemia risk.Source pending | Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely. |
| Insulin (Long-Acting) | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
Frequently asked questions about Retatrutide
Retatrutide is a glp1. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Retatrutide is commonly discussed in the context of supporting weight-loss, blood-sugar, and cardiovascular. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Retatrutide, it is typically administered by injection, it is typically taken null, and its approximate half-life is 144 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
Retatrutide carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Retatrutide is classified as a controlled substance in some jurisdictions, so legal status and prescribing rules apply. Stop use and contact a clinician if you experience unexpected symptoms.
As a supplement, Retatrutide can overlap with other supplements, prescription medicines, hormones and peptides. With a reported plasma half-life near 144 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Retatrutide with no sign-up.
Whether Retatrutide fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Retatrutide. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A long plasma half-life of about 144 hours means Retatrutide is commonly dosed every few days or weekly rather than daily. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 144 hours, a single missed dose of Retatrutide usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Retatrutide the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Retatrutide?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial(opens PubMed in a new tab)N Engl J Med · 2023 · PMID 37366315 · https://pubmed.ncbi.nlm.nih.gov/37366315/
- 2.Retatrutide-A Game Changer in Obesity Pharmacotherapy(opens PubMed in a new tab)Biomolecules · 2025 · PMID 40563436 · https://pubmed.ncbi.nlm.nih.gov/40563436/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 172898051(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/172898051
Verify at
Publisher search links for Retatrutide. These are places to check the information — they are not citations, so they are not numbered.
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Retatrutide?
Plain-text summary, safe to quote verbatim:
Retatrutide is an investigational drug that acts as a triple-receptor agonist, targeting receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Research on Retatrutide focuses on weight loss, blood sugar control, and heart and circulatory health. Retatrutide is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/retatrutide
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Retatrutide — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/retatrutide
What compounds are similar to Retatrutide?
Others in the glp1 category or studied for the same goals.
Which goals is Retatrutide used for?
Other compounds studied for the same benefits as Retatrutide.
Continue exploring
See every compound DoseRoutine catalogs for these goals.